Drugs / TR4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07272135 | Feb 2018 → Aug 2022 | asthma | Trio Medicines Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TR4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07272135 ↗ |
| Action | Inhibit | “TR4 is a selective beta-2-adrenoceptor antagonist.” NCT07272135 ↗ |